AstraZeneca: Calquence Combo Enhances PFS In First-Line CLL In Phase III Trial

(RTTNews) - AstraZeneca (AZN.L, AZN) announced positive high-level results from an interim analysis of the AMPLIFY Phase III trial, showing that a fixed duration of the company's Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated https://www.nasdaq.com/articles/astrazeneca-calquence-combo-enhances-pfs-first-line-cll-phase-iii-trial